Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020
PRINCETON, N.J. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq MarketSite in Times Square on Wednesday, February 26, 2020 ....
Toggle Summary Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock
PRINCETON, N.J. , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share....
Toggle Summary Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
PRINCETON, N.J. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. ...
Toggle Summary Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla ® , Company’s Lead Product Candidate, Receives FDA Approval Company Plans to Commence Distributing Product to Wholesalers in the Fourth Quarter of 2020 PRINCETON, N.J. , Feb....
Toggle Summary FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin
Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S....
Toggle Summary Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors
Funding to Support the Company’s Commercialization Plans for Twirla ® PRINCETON, N.J. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit  facility with Perceptive...
Toggle Summary Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
PRINCETON, N.J. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the company will present at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco . Al Altomari , Chairman and Chief Executive Officer, will...
Toggle Summary Agile Therapeutics Strengthens Commercial Leadership Team
PRINCETON, N.J. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Kimberly Whelan as Vice President of Market Access. Ms. Whelan has over 35 years of experience in the healthcare industry working in finance,...
Toggle Summary Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco
PRINCETON, N.J. , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 14 at the Hilton San Francisco Union Square ....
Toggle Summary Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
PRINCETON, N.J. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration ( FDA ) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application...
Shadow